{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:30:35Z","timestamp":1793136635805,"version":"4.5.0"},"reference-count":74,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,8]]},"abstract":"\n Aim<\/jats:title>\n \n To assess the comparative efficacy and safety of sodium\u2010glucose co\u2010transporter\u20102 (\n SGLT2<\/jats:styled-content>\n ) inhibitors in adults with type 2 diabetes.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We electronically searched randomized controlled trials (\u226524 weeks) including canagliflozin, dapagliflozin or empagliflozin that were published up to 3 November 2015. Data were collected on cardiometabolic and safety outcomes and synthesized using network meta\u2010analyses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 38 trials (23 997 participants) were included. Compared with placebo, all\n SGLT2<\/jats:styled-content>\n inhibitors reduced glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ), fasting plasma glucose (\n FPG<\/jats:styled-content>\n ), body weight and blood pressure, and slightly increased\n HDL<\/jats:styled-content>\n cholesterol. Canagliflozin 300 mg reduced\n HbA1c<\/jats:styled-content>\n ,\n FPG<\/jats:styled-content>\n and systolic blood pressure and increased\n LDL<\/jats:styled-content>\n cholesterol to a greater extent compared with other inhibitors at any dose. At their highest doses, canagliflozin 300 mg reduced:\n HbA1c<\/jats:styled-content>\n by 0.2% [95% confidence interval (\n CI<\/jats:styled-content>\n ) 0.1\u20130.3] versus both dapagliflozin 10 mg and empagliflozin 25 mg;\n FPG<\/jats:styled-content>\n by 0.6 mmol\/l (95%\n CI<\/jats:styled-content>\n 0.3\u20130.9) and 0.5 mmol\/l (95%\n CI<\/jats:styled-content>\n 0.1\u20130.8) versus dapagliflozin and empagliflozin, respectively; and systolic blood pressure by 2\n mmHg<\/jats:styled-content>\n (95%\n CI<\/jats:styled-content>\n 1.0\u20133.0) versus dapagliflozin; and increased\n LDL<\/jats:styled-content>\n cholesterol by 0.13 mmol\/l (95%\n CI<\/jats:styled-content>\n 0.03\u20130.23) and 0.15 mmol\/l (95%\n CI<\/jats:styled-content>\n 0.06\u20130.23) versus dapagliflozin and empagliflozin, respectively. The highest doses of inhibitors had similar effects on body weight reduction. Canagliflozin 300 and 100 mg increased the risk of hypoglycaemia versus placebo, dapagliflozin 10 mg and empagliflozin 10 mg [odds ratios (\n ORs<\/jats:styled-content>\n ) 1.4\u20131.6]. Dapagliflozin 10 mg increased the risk of urinary tract infection versus placebo and empagliflozin 25 mg (\n ORs<\/jats:styled-content>\n 1.4). All inhibitors similarly increased the risk of genital infection (\n ORs<\/jats:styled-content>\n 4\u20136 versus placebo).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Although they increase the risk of genital infection,\n SGLT2<\/jats:styled-content>\n inhibitors are effective in improving cardiometabolic markers in type 2 diabetes, with canagliflozin 300 mg performing better in this respect than other inhibitors. Further studies will clarify whether these differences are likely to translate into differing long\u2010term outcomes.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12670","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T08:24:13Z","timestamp":1460276653000},"page":"783-794","source":"Crossref","is-referenced-by-count":431,"title":["Efficacy and safety of sodium\u2010glucose co\u2010transporter\u20102 inhibitors in type 2 diabetes mellitus: systematic review and network meta\u2010analysis"],"prefix":"10.1111","volume":"18","author":[{"given":"F.","family":"Zaccardi","sequence":"first","affiliation":[{"name":"Diabetes Research Centre, University of Leicester Leicester UK"},{"name":"Diabetes Research Center, Leicester Diabetes Centre, UHL NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R.","family":"Webb","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester Leicester UK"},{"name":"Diabetes Research Center, Leicester Diabetes Centre, UHL NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Z.","family":"Htike","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester Leicester UK"},{"name":"Diabetes Research Center, Leicester Diabetes Centre, UHL NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Youssef","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester Leicester UK"},{"name":"Diabetes Research Center, Leicester Diabetes Centre, UHL NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Khunti","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester Leicester UK"},{"name":"Diabetes Research Center, Leicester Diabetes Centre, UHL NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester Leicester UK"},{"name":"Diabetes Research Center, Leicester Diabetes Centre, UHL NHS Trust Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60794-7"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12244"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00006"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0800800102"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","unstructured":"Multiple\u2010Treatments Meta\u2010Analysis.Using STATA for network meta\u2010analysis. Available from URL:http:\/\/www.mtm.uoi.gr\/index.php\/stata\u2010routines\u2010for\u2010network\u2010meta\u2010analysis. Accessed 15 February 2016.","DOI":"10.1177\/1536867X1501500403"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1101100206"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1045"},{"key":"e_1_2_7_17_1","unstructured":"DiasS WeltonNJ SuttonAJ AdesAE.NICE Decision Support Unit technical support document 2: a generalised linear model framework for pairwise and network meta\u2010analysis of randomised clinical trials.2014. Available from URL:http:\/\/www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf. Accessed 15 February 2016."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6188"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12464"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-43"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12624"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12428"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12189"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0315"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2364"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12459"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0663"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.05.044"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.935764"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.11.002"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0198-0"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12325"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.511"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12881"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2365"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12543"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12814"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1237"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70120-2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1142"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0072-0"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12187"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0779"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12239"},{"key":"e_1_2_7_60_1","first-page":"A598","article-title":"Network meta\u2010analysis (NMA) to assess relative efficacy measured as percentage of patients treated to HbA1c target with canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sulphonylurea (MET + SU)","volume":"18","author":"Taieb V","year":"2015","journal-title":"Value Health"},{"key":"e_1_2_7_61_1","first-page":"A598","article-title":"Bayesian network meta\u2010analysis (NMA) to assess the relative efficacy of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with insulin","volume":"18","author":"Taieb V","year":"2015","journal-title":"Value Health"},{"key":"e_1_2_7_62_1","first-page":"A598","article-title":"A network meta\u2010analysis (NMA) to assess the longer\u2010term relative efficacy of canagliflozin in patients with type 2 diabetes inadequately controlled on metformin","volume":"18","author":"Taieb V","year":"2015","journal-title":"Value Health"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"e_1_2_7_66_1","unstructured":"ClinicalTrials.gov. Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01730534. Accessed 15 February 2016."},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01746.x"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01517.x"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.58"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0890"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251"},{"key":"e_1_2_7_73_1","unstructured":"Food and Drug Administration. Available from URL:http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM461790.pdf. Accessed 15 February 2016."},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3167"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(16)00052\u20108"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12670","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:25:45Z","timestamp":1761873945000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/dom.12670"],"URL":"https:\/\/doi.org\/10.1111\/dom.12670","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]}}}